Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Price Target at $13.75

Theravance Biopharma, Inc. (NASDAQ:TBPH) has received a consensus recommendation of “Hold” from the five research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $13.75.

Several research firms recently issued reports on TBPH. StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th. Leerink Partnrs cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. TD Cowen lowered their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Finally, Leerink Partners cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th.

Theravance Biopharma Trading Up 0.5 %

TBPH stock opened at $8.10 on Wednesday. The company has a market capitalization of $396.25 million, a PE ratio of -9.42 and a beta of 0.24. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.71. The business’s fifty day moving average price is $8.55 and its 200 day moving average price is $8.84.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The firm had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same quarter in the prior year, the firm posted ($0.28) EPS. Research analysts predict that Theravance Biopharma will post -1.04 EPS for the current fiscal year.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Eli Samaha bought 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The stock was purchased at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the acquisition, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The disclosure for this purchase can be found here. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Theravance Biopharma by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,824 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Theravance Biopharma in the 2nd quarter valued at about $108,000. Gerber LLC purchased a new stake in shares of Theravance Biopharma in the 4th quarter valued at about $112,000. XTX Topco Ltd purchased a new stake in shares of Theravance Biopharma in the 2nd quarter valued at about $129,000. Finally, State Board of Administration of Florida Retirement System raised its stake in Theravance Biopharma by 28.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 4,990 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.